A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1

Trial Profile

A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms NIBIT-MESO-1
  • Most Recent Events

    • 18 Oct 2017 Results of the final analysis, presented at the 18th World Conference on Lung Cancer
    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 18th World Conference on Lung Cancer
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top